Table 3.

Costs per LYG compared with no screening and ICER of the cost-effective screening strategies, in a population with realistic attendance^* at the screening programme

Strategy†	Test (cut-off)	Start age (y)	Stop age (y)	Interval (y)	LYG (y)	Costs (€)	Costs/LYG (€)	ICER‡ (€)
1	1s FIT (50)	60	69	3	52	110 000	2115	2115
2	1s FIT (50)	60	70	2	67	147 000	2200	2500
3	1s FIT (50)	60	74	2	80	194 000	2420	3524
4	1s FIT (50)	55	75	2	97	261 000	2688	3956
5	1s FIT (50)	55	74.5	1.5	107	306 000	2865	4613
6	1s FIT (50)	55	79	1.5	119	377 000	3159	5678
7	1s FIT (50)	50	80	1.5	131	463 000	3541	7480
8	1s FIT (50)	55	80	1	137	522 000	3806	9427
9	1s FIT (50)	50	80	1	147	615 000	4191	9590
10	1s FIT (50)	45	80	1	151	704 000	4667	22 099
11	2s FIT ≥1s pos. (50)	45	80	1	153	835 000	5444	51 336

Costs and LYG are expressed per 1000 individuals aged 45 years and older in 2005.

The strategies are in ascending order from least to most costly.

The screening interventions were modelled from the year 2005, all individuals were invited for screening until they reached the end age for that particular screening strategy, and healthcare costs for each individual were calculated until death. Costs and LYG were discounted at an annual rate of 3%.

^*Attendance rate was 60% for screening, 85% for diagnostic colonoscopies, and 80% for surveillance colonoscopies.

^†The strategy number corresponds to the strategies on the efficient frontier in figure 3.

^‡The ICER of an efficient strategy is determined by comparing its additional costs and effects with those of the next less costly and less effective efficient strategy.

FIT, faecal immunochemical test; ICER, incremental cost-effectiveness ratio; LYG, life-years gained.